| Name | VU534 |
|---|---|
| Synonyms |
N-(5,7-Dimethyl-2-benzothiazolyl)-1-[(4-fluorophenyl)sulfonyl]-4-piperidinecboxamide
N-(5,7-Dimethylbenzo[d]thiazol-2-yl)-1-((4-fluorophenyl)sulfonyl)piperidine-4-cboxamide |
| Description | VU534 is a NAPE-PLD activator, with an EC50 of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC50 of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study [1] . |
|---|---|
| Related Catalog | |
| Target |
NAPE-PLD activator, with an EC50 of 0.30 μM |
| References |
| Molecular Formula | C21H22FN3O3S2 |
|---|---|
| Molecular Weight | 447.55 |